JP2004513920A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004513920A5 JP2004513920A5 JP2002542381A JP2002542381A JP2004513920A5 JP 2004513920 A5 JP2004513920 A5 JP 2004513920A5 JP 2002542381 A JP2002542381 A JP 2002542381A JP 2002542381 A JP2002542381 A JP 2002542381A JP 2004513920 A5 JP2004513920 A5 JP 2004513920A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- inhibitor
- hypertension
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000003839 salts Chemical class 0.000 description 62
- 206010020772 Hypertension Diseases 0.000 description 19
- 239000002461 renin inhibitor Substances 0.000 description 18
- 229940086526 renin-inhibitors Drugs 0.000 description 18
- 150000001875 compounds Chemical class 0.000 description 14
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 239000003814 drug Substances 0.000 description 13
- 102000003729 Neprilysin Human genes 0.000 description 12
- 108090000028 Neprilysin Proteins 0.000 description 12
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 12
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 12
- 201000010099 disease Diseases 0.000 description 11
- 229940124597 therapeutic agent Drugs 0.000 description 11
- 208000010125 myocardial infarction Diseases 0.000 description 10
- -1 3-amino-2,2-dimethyl-3-oxopropyl Chemical group 0.000 description 9
- 208000001647 Renal Insufficiency Diseases 0.000 description 8
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 8
- 239000003112 inhibitor Substances 0.000 description 8
- 201000006370 kidney failure Diseases 0.000 description 8
- 206010019280 Heart failures Diseases 0.000 description 7
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 7
- 239000002934 diuretic Substances 0.000 description 7
- 230000001882 diuretic effect Effects 0.000 description 7
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- 201000001320 Atherosclerosis Diseases 0.000 description 6
- 206010007559 Cardiac failure congestive Diseases 0.000 description 6
- 208000031226 Hyperlipidaemia Diseases 0.000 description 6
- 206010042957 Systolic hypertension Diseases 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 208000020832 chronic kidney disease Diseases 0.000 description 6
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 230000009977 dual effect Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 208000037803 restenosis Diseases 0.000 description 6
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 6
- 229940123338 Aldosterone synthase inhibitor Drugs 0.000 description 5
- 239000000400 angiotensin II type 1 receptor blocker Substances 0.000 description 5
- 208000029078 coronary artery disease Diseases 0.000 description 5
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 4
- 239000005541 ACE inhibitor Substances 0.000 description 4
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 4
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 4
- 239000004072 C09CA03 - Valsartan Substances 0.000 description 4
- 229940127291 Calcium channel antagonist Drugs 0.000 description 4
- 108010061435 Enalapril Proteins 0.000 description 4
- 206010048554 Endothelial dysfunction Diseases 0.000 description 4
- 208000010412 Glaucoma Diseases 0.000 description 4
- 229940123934 Reductase inhibitor Drugs 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 239000002170 aldosterone antagonist Substances 0.000 description 4
- 229940083712 aldosterone antagonist Drugs 0.000 description 4
- 229960005370 atorvastatin Drugs 0.000 description 4
- 239000000480 calcium channel blocker Substances 0.000 description 4
- 229960000873 enalapril Drugs 0.000 description 4
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 4
- 230000008694 endothelial dysfunction Effects 0.000 description 4
- 239000002308 endothelin receptor antagonist Substances 0.000 description 4
- 229960003765 fluvastatin Drugs 0.000 description 4
- 229960002797 pitavastatin Drugs 0.000 description 4
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 description 4
- 229960004699 valsartan Drugs 0.000 description 4
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 description 4
- CLPFFLWZZBQMAO-UHFFFAOYSA-N 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 description 3
- 102000005862 Angiotensin II Human genes 0.000 description 3
- 101800000734 Angiotensin-1 Proteins 0.000 description 3
- 102400000344 Angiotensin-1 Human genes 0.000 description 3
- 101800000733 Angiotensin-2 Proteins 0.000 description 3
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 3
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 3
- 206010016654 Fibrosis Diseases 0.000 description 3
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 3
- 208000035150 Hypercholesterolemia Diseases 0.000 description 3
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 3
- 206010022489 Insulin Resistance Diseases 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- 208000018262 Peripheral vascular disease Diseases 0.000 description 3
- 108090000783 Renin Proteins 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 238000002399 angioplasty Methods 0.000 description 3
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 3
- 229950006323 angiotensin ii Drugs 0.000 description 3
- 230000001028 anti-proliverative effect Effects 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 210000004351 coronary vessel Anatomy 0.000 description 3
- 208000033679 diabetic kidney disease Diseases 0.000 description 3
- 230000001258 dyslipidemic effect Effects 0.000 description 3
- 229950011548 fadrozole Drugs 0.000 description 3
- 230000004761 fibrosis Effects 0.000 description 3
- 229960002003 hydrochlorothiazide Drugs 0.000 description 3
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 3
- 208000020346 hyperlipoproteinemia Diseases 0.000 description 3
- 208000003532 hypothyroidism Diseases 0.000 description 3
- 230000002989 hypothyroidism Effects 0.000 description 3
- 208000017169 kidney disease Diseases 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- LVRLSYPNFFBYCZ-VGWMRTNUSA-N omapatrilat Chemical compound C([C@H](S)C(=O)N[C@H]1CCS[C@H]2CCC[C@H](N2C1=O)C(=O)O)C1=CC=CC=C1 LVRLSYPNFFBYCZ-VGWMRTNUSA-N 0.000 description 3
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 3
- 239000002464 receptor antagonist Substances 0.000 description 3
- 229940044551 receptor antagonist Drugs 0.000 description 3
- 238000007634 remodeling Methods 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229960000528 amlodipine Drugs 0.000 description 2
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 2
- 239000003886 aromatase inhibitor Substances 0.000 description 2
- 229960004530 benazepril Drugs 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 229960001208 eplerenone Drugs 0.000 description 2
- JUKPWJGBANNWMW-VWBFHTRKSA-N eplerenone Chemical compound C([C@@H]1[C@]2(C)C[C@H]3O[C@]33[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)C(=O)OC)C[C@@]21CCC(=O)O1 JUKPWJGBANNWMW-VWBFHTRKSA-N 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 description 2
- BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 2
- PHWXUGHIIBDVKD-UHFFFAOYSA-N sitaxentan Chemical compound CC1=NOC(NS(=O)(=O)C2=C(SC=C2)C(=O)CC=2C(=CC=3OCOC=3C=2)C)=C1Cl PHWXUGHIIBDVKD-UHFFFAOYSA-N 0.000 description 2
- 229960002578 sitaxentan Drugs 0.000 description 2
- MDTNUYUCUYPIHE-UHFFFAOYSA-N sodium;(4-chloro-3-methyl-1,2-oxazol-5-yl)-[2-[2-(6-methyl-1,3-benzodioxol-5-yl)acetyl]thiophen-3-yl]sulfonylazanide Chemical compound [Na+].CC1=NOC([N-]S(=O)(=O)C2=C(SC=C2)C(=O)CC=2C(=CC=3OCOC=3C=2)C)=C1Cl MDTNUYUCUYPIHE-UHFFFAOYSA-N 0.000 description 2
- 229960002909 spirapril Drugs 0.000 description 2
- 108700035424 spirapril Proteins 0.000 description 2
- HRWCVUIFMSZDJS-SZMVWBNQSA-N spirapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2(C1)SCCS2)C(O)=O)CC1=CC=CC=C1 HRWCVUIFMSZDJS-SZMVWBNQSA-N 0.000 description 2
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 description 2
- TXSINLUUGRGAJO-WCBMZHEXSA-N (2s)-2-[[(2s)-2-(1,3-benzodioxol-5-ylmethyl)-3-sulfanylpropanoyl]amino]propanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](CS)CC1=CC=C2OCOC2=C1 TXSINLUUGRGAJO-WCBMZHEXSA-N 0.000 description 1
- BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 description 1
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical class O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 1
- VDSBXXDKCUBMQC-HNGSOEQISA-N (4r,6s)-6-[(e)-2-[2-(4-fluoro-3-methylphenyl)-4,4,6,6-tetramethylcyclohexen-1-yl]ethenyl]-4-hydroxyoxan-2-one Chemical compound C1=C(F)C(C)=CC(C=2CC(C)(C)CC(C)(C)C=2\C=C\[C@H]2OC(=O)C[C@H](O)C2)=C1 VDSBXXDKCUBMQC-HNGSOEQISA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- FHHHOYXPRDYHEZ-COXVUDFISA-N Alacepril Chemical compound CC(=O)SC[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 FHHHOYXPRDYHEZ-COXVUDFISA-N 0.000 description 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
- 102000008873 Angiotensin II receptor Human genes 0.000 description 1
- 108050000824 Angiotensin II receptor Proteins 0.000 description 1
- 102000004881 Angiotensinogen Human genes 0.000 description 1
- 108090001067 Angiotensinogen Proteins 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
- 229940122815 Aromatase inhibitor Drugs 0.000 description 1
- 239000002083 C09CA01 - Losartan Substances 0.000 description 1
- 239000002080 C09CA02 - Eprosartan Substances 0.000 description 1
- 239000002947 C09CA04 - Irbesartan Substances 0.000 description 1
- 239000002081 C09CA05 - Tasosartan Substances 0.000 description 1
- 239000002053 C09CA06 - Candesartan Substances 0.000 description 1
- 239000005537 C09CA07 - Telmisartan Substances 0.000 description 1
- UXOWGYHJODZGMF-QORCZRPOSA-N CC(C)[C@H](C[C@@H]([C@H](C[C@@H](C(C)C)C(NCC(C)(C)C(N)=O)=O)O)N)Cc(cc1)cc(OCCCOC)c1OC Chemical compound CC(C)[C@H](C[C@@H]([C@H](C[C@@H](C(C)C)C(NCC(C)(C)C(N)=O)=O)O)N)Cc(cc1)cc(OCCCOC)c1OC UXOWGYHJODZGMF-QORCZRPOSA-N 0.000 description 1
- VGMFHMLQOYWYHN-UHFFFAOYSA-N Compactin Natural products OCC1OC(OC2C(O)C(O)C(CO)OC2Oc3cc(O)c4C(=O)C(=COc4c3)c5ccc(O)c(O)c5)C(O)C(O)C1O VGMFHMLQOYWYHN-UHFFFAOYSA-N 0.000 description 1
- 235000003392 Curcuma domestica Nutrition 0.000 description 1
- 244000008991 Curcuma longa Species 0.000 description 1
- 108010007859 Lisinopril Proteins 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 239000005480 Olmesartan Substances 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- 102100028255 Renin Human genes 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- VXDSGTRNDFHIJB-QQPOVDNESA-N [(1s,4ar)-8-[2-[(2r,4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1CCC[C@@H](C21)OC(=O)[C@@H](C)CC)=CC(C)C2CC[C@@H]1C[C@@H](O)CC(=O)O1 VXDSGTRNDFHIJB-QQPOVDNESA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 229950007884 alacepril Drugs 0.000 description 1
- 229960002478 aldosterone Drugs 0.000 description 1
- 150000001325 aldosterones Chemical class 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940046844 aromatase inhibitors Drugs 0.000 description 1
- 229960004067 benazeprilat Drugs 0.000 description 1
- MADRIHWFJGRSBP-ROUUACIJSA-N benazeprilat Chemical compound C([C@H](N[C@H]1CCC2=CC=CC=C2N(C1=O)CC(=O)O)C(O)=O)CC1=CC=CC=C1 MADRIHWFJGRSBP-ROUUACIJSA-N 0.000 description 1
- KKBIUAUSZKGNOA-HNAYVOBHSA-N benzyl (2s)-2-[[(2s)-2-(acetylsulfanylmethyl)-3-(1,3-benzodioxol-5-yl)propanoyl]amino]propanoate Chemical compound O=C([C@@H](NC(=O)[C@@H](CSC(C)=O)CC=1C=C2OCOC2=CC=1)C)OCC1=CC=CC=C1 KKBIUAUSZKGNOA-HNAYVOBHSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 229960000932 candesartan Drugs 0.000 description 1
- SGZAIDDFHDDFJU-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 229960005110 cerivastatin Drugs 0.000 description 1
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 description 1
- GPUADMRJQVPIAS-QCVDVZFFSA-M cerivastatin sodium Chemical compound [Na+].COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 GPUADMRJQVPIAS-QCVDVZFFSA-M 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229960005025 cilazapril Drugs 0.000 description 1
- HHHKFGXWKKUNCY-FHWLQOOXSA-N cilazapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N2[C@@H](CCCN2CCC1)C(O)=O)=O)CC1=CC=CC=C1 HHHKFGXWKKUNCY-FHWLQOOXSA-N 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- 229950003040 dalvastatin Drugs 0.000 description 1
- FEJVSJIALLTFRP-LJQANCHMSA-N darusentan Chemical compound COC1=CC(OC)=NC(O[C@H](C(O)=O)C(OC)(C=2C=CC=CC=2)C=2C=CC=CC=2)=N1 FEJVSJIALLTFRP-LJQANCHMSA-N 0.000 description 1
- 229950008833 darusentan Drugs 0.000 description 1
- 229960005227 delapril Drugs 0.000 description 1
- WOUOLAUOZXOLJQ-MBSDFSHPSA-N delapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N(CC(O)=O)C1CC2=CC=CC=C2C1)CC1=CC=CC=C1 WOUOLAUOZXOLJQ-MBSDFSHPSA-N 0.000 description 1
- VXDSGTRNDFHIJB-UHFFFAOYSA-N dihydrocompactin Natural products C12C(OC(=O)C(C)CC)CCCC2C=CC(C)C1CCC1CC(O)CC(=O)O1 VXDSGTRNDFHIJB-UHFFFAOYSA-N 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229960002680 enalaprilat Drugs 0.000 description 1
- LZFZMUMEGBBDTC-QEJZJMRPSA-N enalaprilat (anhydrous) Chemical compound C([C@H](N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 LZFZMUMEGBBDTC-QEJZJMRPSA-N 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229960004563 eprosartan Drugs 0.000 description 1
- OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 description 1
- 229960000255 exemestane Drugs 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 229950005203 fasidotril Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229960002490 fosinopril Drugs 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229960001195 imidapril Drugs 0.000 description 1
- KLZWOWYOHUKJIG-BPUTZDHNSA-N imidapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1C(N(C)C[C@H]1C(O)=O)=O)CC1=CC=CC=C1 KLZWOWYOHUKJIG-BPUTZDHNSA-N 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229960002198 irbesartan Drugs 0.000 description 1
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229960002394 lisinopril Drugs 0.000 description 1
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 1
- 229960004773 losartan Drugs 0.000 description 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229950009116 mevastatin Drugs 0.000 description 1
- VTRAEEWXHOVJFV-UHFFFAOYSA-N olmesartan Chemical compound CCCC1=NC(C(C)(C)O)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 VTRAEEWXHOVJFV-UHFFFAOYSA-N 0.000 description 1
- 229960005117 olmesartan Drugs 0.000 description 1
- 229950000973 omapatrilat Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 229960002582 perindopril Drugs 0.000 description 1
- IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- 229960001455 quinapril Drugs 0.000 description 1
- JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 description 1
- 229960003401 ramipril Drugs 0.000 description 1
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- 238000011125 single therapy Methods 0.000 description 1
- 230000005995 skin dysfunction Effects 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229960000651 tasosartan Drugs 0.000 description 1
- ADXGNEYLLLSOAR-UHFFFAOYSA-N tasosartan Chemical compound C12=NC(C)=NC(C)=C2CCC(=O)N1CC(C=C1)=CC=C1C1=CC=CC=C1C=1N=NNN=1 ADXGNEYLLLSOAR-UHFFFAOYSA-N 0.000 description 1
- 229960005187 telmisartan Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 235000013976 turmeric Nutrition 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0028151A GB0028151D0 (en) | 2000-11-17 | 2000-11-17 | Combination of organic compounds |
| PCT/EP2001/013241 WO2002040007A1 (en) | 2000-11-17 | 2001-11-15 | Synergistic combinations comprising a renin inhibitor for cardiovascular diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009171142A Division JP2009235107A (ja) | 2000-11-17 | 2009-07-22 | 循環器系疾患のためのレニン阻害剤を含む相乗的組合せ剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004513920A JP2004513920A (ja) | 2004-05-13 |
| JP2004513920A5 true JP2004513920A5 (enExample) | 2009-09-24 |
Family
ID=9903412
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002542381A Withdrawn JP2004513920A (ja) | 2000-11-17 | 2001-11-15 | 循環器系疾患のためのレニン阻害剤を含む相乗的組合せ剤 |
| JP2009171142A Withdrawn JP2009235107A (ja) | 2000-11-17 | 2009-07-22 | 循環器系疾患のためのレニン阻害剤を含む相乗的組合せ剤 |
| JP2013148269A Expired - Lifetime JP6089278B2 (ja) | 2000-11-17 | 2013-07-17 | 循環器系疾患のためのレニン阻害剤を含む相乗的組合せ剤 |
| JP2016214552A Expired - Lifetime JP6373931B2 (ja) | 2000-11-17 | 2016-11-01 | 循環器系疾患のためのレニン阻害剤を含む相乗的組合せ剤 |
| JP2017232474A Expired - Lifetime JP6577994B2 (ja) | 2000-11-17 | 2017-12-04 | 循環器系疾患のためのレニン阻害剤を含む相乗的組合せ剤 |
| JP2018103151A Expired - Lifetime JP6603757B2 (ja) | 2000-11-17 | 2018-05-30 | 循環器系疾患のためのレニン阻害剤を含む相乗的組合せ剤 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009171142A Withdrawn JP2009235107A (ja) | 2000-11-17 | 2009-07-22 | 循環器系疾患のためのレニン阻害剤を含む相乗的組合せ剤 |
| JP2013148269A Expired - Lifetime JP6089278B2 (ja) | 2000-11-17 | 2013-07-17 | 循環器系疾患のためのレニン阻害剤を含む相乗的組合せ剤 |
| JP2016214552A Expired - Lifetime JP6373931B2 (ja) | 2000-11-17 | 2016-11-01 | 循環器系疾患のためのレニン阻害剤を含む相乗的組合せ剤 |
| JP2017232474A Expired - Lifetime JP6577994B2 (ja) | 2000-11-17 | 2017-12-04 | 循環器系疾患のためのレニン阻害剤を含む相乗的組合せ剤 |
| JP2018103151A Expired - Lifetime JP6603757B2 (ja) | 2000-11-17 | 2018-05-30 | 循環器系疾患のためのレニン阻害剤を含む相乗的組合せ剤 |
Country Status (31)
| Country | Link |
|---|---|
| US (4) | US8168616B1 (enExample) |
| EP (7) | EP1930000A1 (enExample) |
| JP (6) | JP2004513920A (enExample) |
| KR (6) | KR20080096715A (enExample) |
| CN (4) | CN101264073A (enExample) |
| AT (2) | ATE317692T1 (enExample) |
| AU (2) | AU2002223680B2 (enExample) |
| BR (1) | BR0115411A (enExample) |
| CA (2) | CA2763223A1 (enExample) |
| CY (5) | CY1105603T1 (enExample) |
| CZ (2) | CZ305341B6 (enExample) |
| DE (3) | DE60134349D1 (enExample) |
| DK (3) | DK1915993T3 (enExample) |
| EC (1) | ECSP034603A (enExample) |
| ES (4) | ES2734523T3 (enExample) |
| GB (1) | GB0028151D0 (enExample) |
| HU (2) | HU230882B1 (enExample) |
| IL (3) | IL155707A (enExample) |
| LU (2) | LU91563I2 (enExample) |
| MX (1) | MXPA03004358A (enExample) |
| NL (2) | NL300385I1 (enExample) |
| NO (2) | NO334002B1 (enExample) |
| NZ (6) | NZ525795A (enExample) |
| PL (3) | PL400915A1 (enExample) |
| PT (3) | PT1915993E (enExample) |
| RU (2) | RU2310443C2 (enExample) |
| SG (1) | SG135969A1 (enExample) |
| SI (3) | SI1341533T1 (enExample) |
| SK (1) | SK287881B6 (enExample) |
| WO (1) | WO2002040007A1 (enExample) |
| ZA (1) | ZA200303497B (enExample) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1571668A (zh) * | 2001-10-18 | 2005-01-26 | 诺瓦提斯公司 | At1－受体拮抗剂和心血管药物形成的盐 |
| KR20100137026A (ko) * | 2002-05-17 | 2010-12-29 | 노파르티스 아게 | 레닌 억제제, 칼슘 채널 차단제 및 이뇨제를 포함하는 약제학적 조성물 |
| GB0212410D0 (en) * | 2002-05-29 | 2002-07-10 | Novartis Ag | Organic compounds |
| AU2003250858A1 (en) * | 2002-06-28 | 2004-01-19 | Novartis Ag | Use of organic compounds |
| WO2004002466A1 (en) * | 2002-06-28 | 2004-01-08 | Speedel Pharma Ag | Pharmaceutical formulation comprising non-peptide renin inhibitor and surfactant |
| SE0300988D0 (sv) * | 2003-04-03 | 2003-04-03 | Astrazeneca Ab | New use |
| TW200513461A (en) | 2003-10-01 | 2005-04-16 | Speedel Experimenta Ag | Organische verbindungen |
| GB0325605D0 (en) * | 2003-11-03 | 2003-12-10 | Novartis Ag | Combination of organic compounds |
| CA2600973C (en) * | 2003-11-26 | 2012-08-07 | Novartis Ag | .delta.-amino-.gamma.-hydroxy-.omega.-aryl-alkanoic acid |
| GB0327839D0 (en) * | 2003-12-01 | 2003-12-31 | Novartis Ag | Organic compounds |
| BRPI0506490A (pt) * | 2004-01-23 | 2007-02-13 | Speedel Experimenta Ag | compostos orgánicos |
| TW200535131A (en) * | 2004-01-23 | 2005-11-01 | Speedel Experimenta Ag | Organic compounds |
| DE602005025344D1 (de) * | 2004-01-23 | 2011-01-27 | Novartis Ag | Aminoalkoholderivate und deren wirkung als renininhibitoren |
| MY144477A (en) | 2004-03-17 | 2011-09-30 | Novartis Ag | Galenic formulations of organic compounds |
| RU2426532C2 (ru) * | 2004-03-17 | 2011-08-20 | Новартис Аг | Применение органических соединений |
| WO2005090304A1 (en) * | 2004-03-19 | 2005-09-29 | Speedel Experimenta Ag | Organic compounds |
| WO2005099695A1 (en) * | 2004-04-19 | 2005-10-27 | Novartis Ag | Drug delivery systems for the prevention and treatment of vascular diseases |
| RU2407523C2 (ru) * | 2004-10-08 | 2010-12-27 | Новартис Аг | Применение ингибиторов ренина для профилактики или лечения диастолической дисфункции или диастолической сердечной недостаточности |
| GB0428250D0 (en) * | 2004-12-23 | 2005-01-26 | Novartis Ag | Organic compounds |
| MY146830A (en) * | 2005-02-11 | 2012-09-28 | Novartis Ag | Combination of organic compounds |
| EP1897879A3 (en) | 2005-03-31 | 2008-06-11 | Speedel Experimenta AG | 2,4,5-substituted piperidines as renin inhibitors |
| TW200722424A (en) | 2005-03-31 | 2007-06-16 | Speedel Experimenta Ag | Substituted piperidines |
| BRPI0609915A2 (pt) * | 2005-04-27 | 2010-05-25 | Novartis Ag | métodos para tratar aterosclerose |
| GB0511686D0 (en) * | 2005-06-08 | 2005-07-13 | Novartis Ag | Organic compounds |
| CN1732952B (zh) * | 2005-09-02 | 2010-04-07 | 姚俊华 | 一种治疗高血压的复方分散片 |
| US8158146B2 (en) | 2005-09-28 | 2012-04-17 | Teva Pharmaceutical Industries Ltd. | Stable combinations of amlodipine besylate and benazepril hydrochloride |
| EP1930008A1 (en) * | 2005-09-28 | 2008-06-11 | Teva Pharmaceutical Industries Ltd | Sable composition of benazepril hydrochloride |
| EP1951309A2 (en) * | 2005-11-08 | 2008-08-06 | Novartis AG | Combination of an angiotensin ii receptor blocker, a calcium channel blocker and another active agent |
| AR057882A1 (es) | 2005-11-09 | 2007-12-26 | Novartis Ag | Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra |
| BRPI0708879A2 (pt) * | 2006-03-13 | 2011-06-14 | Encysive Pharmaceuticals | peocessos e composiÇÕes para o tratamento de insufiÊncia cardÍaca diastàlica |
| US20070260203A1 (en) * | 2006-05-04 | 2007-11-08 | Allergan, Inc. | Vasoactive agent intraocular implant |
| GB0612540D0 (en) | 2006-06-23 | 2006-08-02 | Novartis Ag | Galenical formulations of organic compounds |
| TW200831463A (en) * | 2006-09-12 | 2008-08-01 | Speedel Experimenta Ag | Nitrate esters of aminoalcohols |
| KR100888131B1 (ko) * | 2006-10-10 | 2009-03-11 | 한올제약주식회사 | 시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제 |
| BRPI0721167A2 (pt) * | 2006-12-15 | 2014-03-18 | Novartis Ag | Inibidores de renina para prevenção e tratamento de hipertensão em pacientes obesos. |
| EP2120899A1 (en) * | 2007-02-14 | 2009-11-25 | Gilead Colorado, Inc. | Antihypertensive drug combination |
| AR066168A1 (es) * | 2007-09-28 | 2009-07-29 | Novartis Ag | Formulaciones galenicas de compuestos organicos |
| EP2062874B1 (en) | 2007-11-20 | 2014-12-17 | KRKA, tovarna zdravil, d.d., Novo mesto | Process and intermediates for the preparation of aliskiren |
| WO2009104939A2 (ko) | 2008-02-22 | 2009-08-27 | 한올제약주식회사 | 약제학적 제제 |
| WO2009125981A2 (ko) | 2008-04-10 | 2009-10-15 | 한올제약주식회사 | 약제학적 제제 |
| WO2009127251A1 (en) * | 2008-04-16 | 2009-10-22 | Novartis Ag | Combinations comprising a renin inhibitor |
| KR101209319B1 (ko) | 2008-04-29 | 2012-12-06 | 한올바이오파마주식회사 | 안지오텐신-ⅱ-수용체 차단제를 포함하는 약제학적 제제 |
| WO2010024772A1 (en) * | 2008-08-29 | 2010-03-04 | Medivir Ab | Aspartyl protease inhibitors |
| SI2189442T1 (sl) | 2008-11-20 | 2015-03-31 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Postopek in intermediati za pripravo aliskirena |
| CN102348452A (zh) | 2009-03-20 | 2012-02-08 | 诺瓦提斯公司 | 缬沙坦和阿利吉仑的固定剂量组合的盖仑制剂 |
| CN101926793B (zh) * | 2010-08-05 | 2012-08-15 | 成都自豪药业有限公司 | 一种含替米沙坦和阿利吉伦的联合用药物及其制备方法 |
| EP2704706A1 (en) | 2011-05-06 | 2014-03-12 | Artskin D.O.O. | Composition comprising angiotensin ii receptor antagonist and antioxidant for maintaining and/or improving skin properties |
| RU2483750C1 (ru) * | 2012-03-19 | 2013-06-10 | Общество с ограниченной ответственностью "СупраГен" | Способ лечения больных с острым инфарктом миокарда с подъемом сегмента st |
| CN104619345A (zh) * | 2012-05-18 | 2015-05-13 | 罗达制药有限公司 | 液体制剂 |
| RU2554815C1 (ru) * | 2014-06-18 | 2015-06-27 | Общество с ограниченной ответственностью "Нанолек" | Гипотензивное средство |
| AU2015295845B2 (en) | 2014-07-30 | 2020-03-05 | Merck Patent Gmbh | Directly compressible polyvinyl alcohols |
| SG11201903803UA (en) * | 2016-10-27 | 2019-05-30 | Damian Pharma Ag | Aldosterone synthase inhibitor |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4617307A (en) | 1984-06-20 | 1986-10-14 | Ciba-Geigy Corporation | Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors |
| US4889861A (en) | 1982-12-21 | 1989-12-26 | Ciba-Geigy Corp. | Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors |
| US4559332A (en) | 1983-04-13 | 1985-12-17 | Ciba Geigy Corporation | 20-Spiroxanes and analogues having an open ring E, processes for their manufacture, and pharmaceutical preparations thereof |
| US4782043A (en) | 1983-06-15 | 1988-11-01 | Merck & Co., Inc. | Renin inhibitors containing a C-terminal amide cycle |
| US4898729A (en) | 1983-12-09 | 1990-02-06 | Euroceltique, S.A. | Treatment of hypertension, compounds and compositions for antihypertension and diuresis |
| US4812442A (en) | 1984-05-29 | 1989-03-14 | Merck & Co., Inc. | Tripeptide renin inhibitors |
| CA1334092C (en) | 1986-07-11 | 1995-01-24 | David John Carini | Angiotensin ii receptor blocking imidazoles |
| US5594021A (en) | 1993-05-20 | 1997-01-14 | Texas Biotechnology Corporation | Thienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that modulate the activity of endothelin |
| US4927807A (en) | 1987-10-06 | 1990-05-22 | Abbott Laboratories | Glaucoma treatment |
| SE8802428D0 (sv) * | 1988-06-28 | 1988-06-28 | Haessle Ab | New compounds |
| US5268374A (en) | 1988-10-04 | 1993-12-07 | Abbott Laboratories | Non-peptide renin inhibitors |
| US5164388A (en) | 1988-10-19 | 1992-11-17 | Abbott Laboratories | Heterocyclic peptide renin inhibitors |
| SG52330A1 (en) | 1989-06-14 | 1998-09-28 | Smithkline Beecham Corp | Imidazolyl-alkenoic acids |
| EP0438311A3 (en) * | 1990-01-19 | 1992-07-01 | Merck & Co. Inc. | Di- and tripeptide renin inhibitors |
| US5182266A (en) * | 1990-01-31 | 1993-01-26 | Abbott Laboratories | Method for treating renal disease |
| EP0443983B1 (de) | 1990-02-19 | 1996-02-28 | Ciba-Geigy Ag | Acylverbindungen |
| TW201738B (enExample) | 1990-03-20 | 1993-03-11 | Sanofi Co | |
| US5196444A (en) | 1990-04-27 | 1993-03-23 | Takeda Chemical Industries, Ltd. | 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof |
| ES2097208T3 (es) * | 1990-05-11 | 1997-04-01 | Pfizer | Composiciones y procedimientos terapeuticos y sinergicos. |
| US5821232A (en) | 1990-05-11 | 1998-10-13 | Pfizer Inc. | Synergistic therapeutic compositions and methods |
| IE68045B1 (en) | 1990-05-11 | 1996-05-15 | Abbott Lab | Renin inhibitors |
| WO1992000972A1 (en) | 1990-07-11 | 1992-01-23 | Abbott Laboratories | Renin inhibiting compounds |
| WO1992003429A1 (en) * | 1990-08-15 | 1992-03-05 | Abbott Laboratories | Renin inhibitors |
| US5656650A (en) * | 1990-12-14 | 1997-08-12 | Smithkline Beecham Corp. | Angiotensin II receptor blocking compositions |
| EP0565634B1 (en) | 1990-12-14 | 1999-03-17 | Smithkline Beecham Corporation | Angiotensin ii receptor blocking compositions |
| EP0498361A3 (en) | 1991-02-06 | 1992-09-02 | Schering Corporation | Combination of an angiotensin ii antagonist or renin inhibitor with a neutral endopeptidase inhibitor |
| CA2229000C (en) | 1991-02-21 | 2002-04-09 | Sankyo Company, Limited | 1-biphenylimidazole derivatives, their preparation and their therapeutic use |
| RU2086544C1 (ru) * | 1991-06-13 | 1997-08-10 | Хоффманн-Ля Рош АГ | Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина |
| DE4121975A1 (de) | 1991-07-03 | 1993-01-07 | Basf Ag | Thermoplastische formmassen auf der basis von polycarbonaten, styrol/acrylnitril-polymerisaten und polyolefinen |
| US5256667A (en) | 1991-09-25 | 1993-10-26 | Merck & Co., Inc. | Quinazolinones and pyridopyrimidinones |
| TW226375B (enExample) | 1991-10-24 | 1994-07-11 | American Home Prod | |
| US6057344A (en) | 1991-11-26 | 2000-05-02 | Sepracor, Inc. | Methods for treating hypertension, and angina using optically pure (-) amlodipine |
| DK0699069T3 (da) | 1993-04-27 | 2002-05-27 | Smithkline Beecham Corp | Endothelinreceptorantagonister |
| US5508272A (en) * | 1993-06-15 | 1996-04-16 | Bristol-Myers Squibb Company | Compounds containing a fused bicycle ring and processes therefor |
| ES2154277T3 (es) * | 1993-07-15 | 2001-04-01 | Hoffmann La Roche | Combinacion farmaceutica que contiene un inhibidor del sistema renina-angiotensina y un antagonista de endotelina. |
| DK0714897T3 (da) | 1993-08-18 | 2001-03-19 | Banyu Pharma Co Ltd | Ring-kondenseret heteroaromatisk cyclopentenderivat med endothelinantagonist-aktivitet |
| US5606078A (en) | 1994-04-18 | 1997-02-25 | Ciba-Geigy Corporation | 3,5-Disubstituted tetrahydrofuran-2-ones |
| US5659065A (en) | 1994-04-18 | 1997-08-19 | Novartis Corporation | Alpha-aminoalkanoic acids and reduction products |
| MY119161A (en) | 1994-04-18 | 2005-04-30 | Novartis Ag | Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities |
| US5562921A (en) | 1994-07-15 | 1996-10-08 | Sherman; Bernard C. | Stable solid pharmaceutical compositions containing enalapril maleate |
| AU711832B2 (en) | 1994-08-19 | 1999-10-21 | Abbvie Bahamas Ltd. | Endothelin antagonists |
| US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
| DE19533023B4 (de) | 1994-10-14 | 2007-05-16 | Basf Ag | Neue Carbonsäurederivate, ihre Herstellung und Verwendung |
| TW313568B (enExample) | 1994-12-20 | 1997-08-21 | Hoffmann La Roche | |
| NZ298853A (en) | 1995-01-27 | 1998-07-28 | Rhone Poulenc Rorer Ltd | 5-[2-cyano-phenoxy]-2-phenyl-acetic acid derivatives |
| US5846990A (en) | 1995-07-24 | 1998-12-08 | Bristol-Myers Squibb Co. | Substituted biphenyl isoxazole sulfonamides |
| JPH0971586A (ja) * | 1995-09-07 | 1997-03-18 | Yamanouchi Pharmaceut Co Ltd | 新規な二環性縮合イミダゾール誘導体 |
| US5696166A (en) | 1995-10-31 | 1997-12-09 | Yanni; John M. | Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders |
| KR100456650B1 (ko) | 1995-12-20 | 2005-06-20 | 야마노우치세이야쿠 가부시키가이샤 | 아릴에텐설폰아미드유도체 |
| IT1277737B1 (it) | 1995-12-28 | 1997-11-12 | Zambon Spa | Derivati tiolici ad attivita' inibitrice delle metallopeptidasi |
| WO1997027314A1 (fr) | 1996-01-23 | 1997-07-31 | Shionogi & Co., Ltd. | Processus de production d'analogues d'acide oleanolique par la culture de racine pileuse |
| EE9800315A (et) | 1996-04-04 | 1999-06-15 | Banyu Pharmaceutical Co., Ltd. | Meetod südamepuudulikkuse käitlemiseks endoteliini antagonistide abil |
| GB9613470D0 (en) | 1996-06-27 | 1996-08-28 | Ciba Geigy Ag | Small solid oral dosage form |
| GT199800126A (es) * | 1997-08-29 | 2000-01-29 | Terapia de combinacion. | |
| DE19806438A1 (de) * | 1998-02-17 | 1999-08-19 | Basf Ag | Neue Carbonsäurederivate mit 5-substituiertem Pyrimidinring, ihre Herstellung und Verwendung |
| WO1999065500A1 (en) * | 1998-06-17 | 1999-12-23 | Bristol-Myers Squibb Company | Preventing cerebral infarction through administration of adp-receptor antiplatelet and antihypertensive drugs in combination |
| TR200100172T2 (tr) | 1998-07-20 | 2001-05-21 | Smithkline Beecham Corporation | Oral katı doz formunda eprosartan içeren biyolojik bakımdan kuvvetlendirilmiş formülasyonlar |
| UA74141C2 (uk) * | 1998-12-09 | 2005-11-15 | Дж.Д. Сірл Енд Ко. | Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти) |
| WO2000056403A1 (en) * | 1999-03-19 | 2000-09-28 | The Brigham And Women's Hospital, Inc. | UPREGULATION OF TYPE III ENDOTHELIAL CELL NITRIC OXIDE SYNTHASE BY HMG-CoA REDUCTASE INHIBITORS |
| ATE370738T1 (de) | 1999-11-09 | 2007-09-15 | Pharmacia Corp | Verwendung von eplerenon zur behandlung von restenose |
| US20030114389A1 (en) * | 2001-11-13 | 2003-06-19 | Webb Randy Lee | Combination of organic compounds |
| KR20100137026A (ko) * | 2002-05-17 | 2010-12-29 | 노파르티스 아게 | 레닌 억제제, 칼슘 채널 차단제 및 이뇨제를 포함하는 약제학적 조성물 |
| ATE397147T1 (de) | 2002-12-31 | 2008-06-15 | Volkswagen Ag | Verfahren zur steuerung einer verbrennungskraftmaschine sowie magerlauffahige verbrennungskraftmaschine |
-
2000
- 2000-11-15 US US10/416,039 patent/US8168616B1/en not_active Expired - Fee Related
- 2000-11-17 GB GB0028151A patent/GB0028151D0/en not_active Ceased
-
2001
- 2001-11-15 NZ NZ525795A patent/NZ525795A/en not_active IP Right Cessation
- 2001-11-15 CN CNA2008100985065A patent/CN101264073A/zh active Pending
- 2001-11-15 AU AU2002223680A patent/AU2002223680B2/en not_active Expired
- 2001-11-15 ES ES10179109T patent/ES2734523T3/es not_active Expired - Lifetime
- 2001-11-15 PL PL40091501A patent/PL400915A1/pl unknown
- 2001-11-15 SG SG200504685-9A patent/SG135969A1/en unknown
- 2001-11-15 NZ NZ568764A patent/NZ568764A/en not_active IP Right Cessation
- 2001-11-15 EP EP20080002604 patent/EP1930000A1/en not_active Withdrawn
- 2001-11-15 CA CA 2763223 patent/CA2763223A1/en not_active Withdrawn
- 2001-11-15 PT PT08002401T patent/PT1915993E/pt unknown
- 2001-11-15 RU RU2003116896A patent/RU2310443C2/ru not_active IP Right Cessation
- 2001-11-15 CZ CZ2011-614A patent/CZ305341B6/cs not_active IP Right Cessation
- 2001-11-15 SI SI200130530T patent/SI1341533T1/sl unknown
- 2001-11-15 CZ CZ20031341A patent/CZ299749B6/cs not_active IP Right Cessation
- 2001-11-15 BR BR0115411A patent/BR0115411A/pt not_active Application Discontinuation
- 2001-11-15 KR KR1020087024051A patent/KR20080096715A/ko not_active Withdrawn
- 2001-11-15 ES ES08002401T patent/ES2429292T3/es not_active Expired - Lifetime
- 2001-11-15 KR KR10-2003-7005901A patent/KR20030051753A/ko not_active Ceased
- 2001-11-15 SI SI200130850T patent/SI1602370T1/sl unknown
- 2001-11-15 CN CNB018190685A patent/CN100404024C/zh not_active Expired - Fee Related
- 2001-11-15 EP EP10179109.3A patent/EP2305232B1/en not_active Expired - Lifetime
- 2001-11-15 DE DE60134349T patent/DE60134349D1/de not_active Expired - Lifetime
- 2001-11-15 ES ES01996377T patent/ES2256335T3/es not_active Expired - Lifetime
- 2001-11-15 NZ NZ550897A patent/NZ550897A/en not_active IP Right Cessation
- 2001-11-15 IL IL155707A patent/IL155707A/en not_active IP Right Cessation
- 2001-11-15 CN CNA200710140212XA patent/CN101091703A/zh active Pending
- 2001-11-15 SI SI200131026T patent/SI1915993T1/sl unknown
- 2001-11-15 EP EP20010996377 patent/EP1341533B1/en not_active Expired - Lifetime
- 2001-11-15 KR KR1020107018819A patent/KR20100114904A/ko not_active Ceased
- 2001-11-15 NZ NZ550896A patent/NZ550896A/en not_active IP Right Cessation
- 2001-11-15 PL PL40091401A patent/PL400914A1/pl unknown
- 2001-11-15 EP EP20050015603 patent/EP1602370B1/en not_active Revoked
- 2001-11-15 PL PL361404A patent/PL227576B1/pl unknown
- 2001-11-15 NZ NZ537691A patent/NZ537691A/en not_active IP Right Cessation
- 2001-11-15 KR KR1020087001407A patent/KR20080011355A/ko not_active Ceased
- 2001-11-15 NZ NZ550898A patent/NZ550898A/en not_active IP Right Cessation
- 2001-11-15 DE DE200912000021 patent/DE122009000021I1/de active Pending
- 2001-11-15 HU HUP1400409A patent/HU230882B1/hu not_active IP Right Cessation
- 2001-11-15 AT AT01996377T patent/ATE317692T1/de active
- 2001-11-15 EP EP20100179101 patent/EP2305231A1/en not_active Withdrawn
- 2001-11-15 SK SK584-2003A patent/SK287881B6/sk not_active IP Right Cessation
- 2001-11-15 EP EP20080002401 patent/EP1915993B1/en not_active Revoked
- 2001-11-15 DK DK08002401T patent/DK1915993T3/da active
- 2001-11-15 JP JP2002542381A patent/JP2004513920A/ja not_active Withdrawn
- 2001-11-15 PT PT05015603T patent/PT1602370E/pt unknown
- 2001-11-15 KR KR1020117012347A patent/KR101258365B1/ko not_active Expired - Fee Related
- 2001-11-15 ES ES05015603T patent/ES2308347T3/es not_active Expired - Lifetime
- 2001-11-15 AU AU2368002A patent/AU2368002A/xx active Pending
- 2001-11-15 WO PCT/EP2001/013241 patent/WO2002040007A1/en not_active Ceased
- 2001-11-15 PT PT01996377T patent/PT1341533E/pt unknown
- 2001-11-15 DE DE2001617295 patent/DE60117295T2/de not_active Expired - Lifetime
- 2001-11-15 MX MXPA03004358A patent/MXPA03004358A/es active IP Right Grant
- 2001-11-15 KR KR1020087024052A patent/KR101008752B1/ko not_active Expired - Fee Related
- 2001-11-15 HU HU0301841A patent/HUP0301841A3/hu not_active Application Discontinuation
- 2001-11-15 AT AT05015603T patent/ATE397445T1/de active
- 2001-11-15 EP EP20100179116 patent/EP2305233A1/en not_active Withdrawn
- 2001-11-15 CN CNA2008100985050A patent/CN101264072A/zh active Pending
- 2001-11-15 DK DK05015603T patent/DK1602370T3/da active
- 2001-11-15 CA CA 2428647 patent/CA2428647A1/en not_active Withdrawn
- 2001-11-15 DK DK01996377T patent/DK1341533T3/da active
-
2003
- 2003-05-07 ZA ZA200303497A patent/ZA200303497B/en unknown
- 2003-05-13 EC ECSP034603 patent/ECSP034603A/es unknown
- 2003-05-16 NO NO20032233A patent/NO334002B1/no not_active IP Right Cessation
-
2006
- 2006-04-13 CY CY20061100519T patent/CY1105603T1/el unknown
- 2006-09-12 RU RU2006132668A patent/RU2346703C2/ru not_active IP Right Cessation
-
2008
- 2008-09-02 CY CY20081100932T patent/CY1108305T1/el unknown
-
2009
- 2009-04-24 NL NL300385C patent/NL300385I1/nl unknown
- 2009-05-06 LU LU91563C patent/LU91563I2/fr unknown
- 2009-05-11 CY CY2009005C patent/CY2009005I2/el unknown
- 2009-07-22 JP JP2009171142A patent/JP2009235107A/ja not_active Withdrawn
-
2011
- 2011-03-31 IL IL212075A patent/IL212075A/en not_active IP Right Cessation
- 2011-09-19 US US13/235,659 patent/US9023893B2/en not_active Expired - Fee Related
- 2011-09-19 US US13/235,787 patent/US8618174B2/en not_active Expired - Fee Related
- 2011-09-19 US US13/235,758 patent/US9023894B2/en not_active Expired - Fee Related
-
2012
- 2012-01-30 IL IL217847A patent/IL217847A0/en unknown
-
2013
- 2013-07-17 JP JP2013148269A patent/JP6089278B2/ja not_active Expired - Lifetime
- 2013-10-10 CY CY20131100889T patent/CY1114829T1/el unknown
- 2013-11-27 LU LU92315C patent/LU92315I2/fr unknown
- 2013-12-13 CY CY2013045C patent/CY2013045I1/el unknown
- 2013-12-17 NO NO2013019C patent/NO2013019I1/no unknown
-
2016
- 2016-11-01 JP JP2016214552A patent/JP6373931B2/ja not_active Expired - Lifetime
-
2017
- 2017-12-04 JP JP2017232474A patent/JP6577994B2/ja not_active Expired - Lifetime
-
2018
- 2018-05-30 JP JP2018103151A patent/JP6603757B2/ja not_active Expired - Lifetime
-
2019
- 2019-09-06 NL NL301005C patent/NL301005I2/nl unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6373931B2 (ja) | 循環器系疾患のためのレニン阻害剤を含む相乗的組合せ剤 | |
| RU2316318C2 (ru) | Фармацевтическая композиция, включающая ингибитор ренина, блокатор кальциевых каналов и диуретик | |
| ES2290429T3 (es) | Composiciones farmaceuticas que comprenden valsartan e inhibidores de nep. | |
| RU2336876C2 (ru) | Комбинация ингибитора дипептидилпептидазы iv (dpp iv) и сердечно-сосудистого вещества | |
| US20080119557A1 (en) | Combination Of Organic Compounds | |
| AU2001258323A1 (en) | Combination of at least two compounds selected from an at1-receptor antagonist or an ace inhibitor or a hmg-co-a reductase inhibitor groups | |
| AU2010200833B2 (en) | Use of renin inhibitors for the prevention or treatment of diastolic dysfunction or diastolic heart failure | |
| WO2007106708A2 (en) | Combinations of the angiotensin ii antagonist valsartan and the nep inhibitor daglutril | |
| AU2005224014B2 (en) | Use of organic compounds | |
| RU2002129558A (ru) | КОМБИНАЦИЯ ПО МЕНЬШЕЙ МЕРЕ ДВУХ СОЕДИНЕНИЙ, ВЫБРАННЫХ ИЗ ГРУПП АНТАГОНИСТОВ АТ,-РЕЦЕПТОРА ИЛИ ИНГИБИТОРОВ АСЕ(АНГИОТЕНЗИНПРЕВРАЩАЮЩИЙ ФЕРМЕНТ) ИЛИ ИНГИБИТОРОВ HMG-COA-РЕДУКТАЗЫ (β-ГИДРОКСИ-β-МЕТИЛГЛУТАРИЛ-КОФЕРМЕНТ-А-РЕДУКТАЗА) | |
| WO2007045663A2 (en) | Combination of an ati receptor antagonist and a np inhibitor fro treating ia hypertension and heartfailure | |
| CN101300030A (zh) | 血管紧张素ⅱ受体阻滞剂、钙通道阻滞剂和另一活性物质的组合产品 | |
| JP2006511542A (ja) | バルサルタンとｃｏｘ−２インヒビターの組み合わせ | |
| CN101151027A (zh) | 有机化合物的组合 | |
| AU2011236117A1 (en) | Use of renin inhibitors for the prevention or treatment of diastolic dysfunction or diastolic heart failure | |
| HK1074774B (en) | Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic | |
| WO2009127251A1 (en) | Combinations comprising a renin inhibitor |